Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella’s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella’s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.
Copyright West LLC. Minimum 15 minutes delayed.
● Covers NASH candidates AXA1125 and AXA1957 as well as other Endogenous Metabolic Modulator (EMM) compositions ● Expands Axcella’s existing composition and method of use portfolio ● Reinforces the strength of Axcella’s strategy to protect its first-mover advantage CAMBRIDGE, Mass.
Completed enrollment of an ongoing non-IND clinical study of AXA1125/AXA1957 in more than 100 adult subjects with NAFLD Announced intent to conduct future studies of AXA1125/AXA1957 under IND as therapeutic candidates for NASH On track to file an IND and initiate a registrational trial of AXA1665
AXA1665 enhances amino acid metabolism and improves ammonia disposal in subjects with mild and moderate hepatic insufficiency AXA1125 impacts key biochemical pathways and molecular mediators regulating amino acid catabolism, insulin sensitivity, inflammation and fibrogenesis Data reinforce product